Cybin (CYBN) announced that the United States Patent and Trademark Office has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD. The patent, which is expected to provide exclusivity until 2041, includes claims to pharmaceutical compositions and oral dosage forms within the Company’s proprietary deuterated psilocin analog program, CYB003.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Secures New U.S. Patent for CYB003 Program in Major Depressive Disorder
- Cybin CEO to Speak at Milken Institute Global Conference on Medical Breakthroughs
- Psychedelic: Clearmind completes clinical site initiations for AUD trial
- Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials
- Cybin announces additional CYB003 strategic partnership agreements
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue